This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Health Policy  • Medical Practice, Other  • Quality of Care  • Quality of Care, Other  • Statistics and Research Methods  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

G. Caleb Alexander, MD, MS; Randall S. Stafford, MD, PhD

JAMA. 2009;301(23):2488-2490.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Researchers, policy makers, insurers, and other stakeholders have voiced enthusiasm about the value of comparative effectiveness research that rigorously evaluates 2 or more drugs or devices. The most recent boost for these efforts has been the US congressional financial stimulus package that contains provisions for $1.1 billion to be devoted to this effort.¹ The appeal of comparative effectiveness research is undeniable. If there is one issue that stakeholders agree about, it is that increasing health care costs are ultimately unsustainable and society needs more value for its money. However, it is not clear that comparative effectiveness research, as it is commonly framed, has a comparative advantage when it comes to improving the US health care system.

If comparative effectiveness research is to succeed, future initiatives will need to (1) generate data prior to the widespread adoption of a drug or . . . [Full Text of this Article]

Need for Greater Timeliness of Comparative Effectiveness Data

Author Affiliations: Department of Medicine, University of Chicago Hospitals and MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, Illinois, and Department of Pharmacy Practice, University of Illinois at Chicago School of Pharmacy (Dr Alexander); and Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California (Dr Stafford).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

The Science of Health Care Reform
Robert H. Brook
JAMA. 2009;301(23):2486-2487.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada
Clement et al.
JAMA 2009;302:1437-1443.
ABSTRACT | FULL TEXT